{"id":1067,"date":"2026-04-16T16:04:58","date_gmt":"2026-04-16T16:04:58","guid":{"rendered":"https:\/\/sites.rutgers.edu\/clinical-research-center\/?p=1067"},"modified":"2026-04-16T16:04:58","modified_gmt":"2026-04-16T16:04:58","slug":"historic-breakthrough-in-epilepsy-treatment-at-rwjuh","status":"publish","type":"post","link":"https:\/\/sites.rutgers.edu\/clinical-research-center\/historic-breakthrough-in-epilepsy-treatment-at-rwjuh\/","title":{"rendered":"Historic Breakthrough in Epilepsy Treatment at RWJUH!\u00a0"},"content":{"rendered":"
A major milestone in neurological innovation has just been achieved. Dr. Robert Gross, Study Principal Investigator, has successfully operated on the\u00a0first participant<\/b>\u00a0to receive the investigational gene therapy\u00a0AMT-260<\/b>, delivered directly into the brain using a highly advanced MRI-guided procedure.<\/div>\n
This landmark procedure is part of a\u00a0first-in-human (FIH)<\/b>\u00a0clinical trial exploring a revolutionary approach to treating adults with unilateral refractory mesial temporal lobe epilepsy (MTLE)\u2014a condition that has remained difficult to treat with conventional therapies. Using MRI-guided convection-enhanced delivery (CED), this cutting-edge technique enables precise, targeted delivery of gene therapy directly to affected brain regions.<\/div>\n
<\/div>\n

\u2728\u00a0A First for RWJUH<\/b>
\nThis achievement marks the\u00a0first patient at RWJUH to receive brain-directed gene therapy<\/b>, a proud and defining moment that highlights the institution\u2019s leadership in advancing next-generation neurological treatments and bringing new hope to patients.<\/p>\n

<\/div>\n

\ud83e\udde0\u00a0About the Study<\/b>
\nThis multi-center, Phase 1\/2a, FIH<\/strong> study is designed to evaluate the safety, tolerability, and efficacy<\/b>\u00a0of AMT-260 in adults with MTLE.<\/p>\n

Participants in the study will:<\/p>\n